Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients.

Slides:



Advertisements
Similar presentations
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Kochenderfer JN et al. Proc ASH 2013;Abstract 168.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Lee DW III et al. Proc ASH 2013;Abstract 68.
T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant in Vivo Proliferation, Complete Responses and Long-Term.
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Blood : R2 임규성.  Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by low platelet counts and may be responsible.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Blood 2011, 117: R1 Seon-Hye Kim Arnaud Jaccarda and Olivier Hermine Journal conference.
SPIRIT 2 Initiation: prepared November Key Facts UK Multicentre study (NCRN adopted) Looking for 810 patients from UK Current status First patient.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
ELIGIBILITY CRITERIA- Summarised
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,
Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
BCT Bortezomib Consolidation Trial
Non-Hodgkin’s Lymphoma
Vose JM et al. Proc ASH 2011;Abstract 661.
R1.이용석 / modulator pf.한재준.
Moskowitz CH et al. Proc ASH 2015;Abstract 182.
Chen R et al. Proc ASH 2015;Abstract 518.
Randomised phase 2 trial in Waldenstrőm's macroglobulinaemia
Alessandra Gennari, MD PhD
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
Maury S et al. Proc ASH 2015;Abstract 1.
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
GTP Scenario # 4 September 17,2005.
CCO Independent Conference Highlights
Oki Y et al. Proc ASH 2013;Abstract 252.
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
ASCT for AL Seok Jin Kim
Nordic sites Sweden Uppsala University Hospital
Biomarker Screening Pilot
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Professor John Gribben Barts Cancer Institute
Feasibility Study) PB-PG
Immunotherapy for lymphoma: The time is now
Tania Tillett Royal United Hospital
Attal M et al. Proc ASCO 2010;Abstract 8018.
M. Bregni, M. Bernardi, P. Servida,
Patient charactaristics:
Ansell SM et al. Proc ASH 2012;Abstract 798.
Results of Phase 1 Trial of Treg Adoptive Cell Transfer in Living Donor Kidney Transplant Recipients TRACT Therapeutics™
A5338 P. G . MARIMBE-NYATSAMBO ANNUAL RESEARCH DAY 8 APRIL 2016.
MTN-037 Protocol Overview
Introduction Case Report Conclusion
ACT II: The Second UK Phase III Anal Cancer Trial
Seymour JF et al. Proc ASH 2013;Abstract 872.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Reduced Intensity Allograft Scopes and Limitations
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- Phase 1 Signalling Study
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
Volume 21, Issue 4, Pages (April 2013)
Foroud shahbazi Pharm.D
Manufacturing and delivery pipeline of genetically modified T-cell therapies. Manufacturing and delivery pipeline of genetically modified T-cell therapies.
Optimizing therapy for nodal marginal zone lymphoma
Presentation transcript:

Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients with resistant or relapsed Diffuse Large B cell Lymphoma (DLBCL) The primary objective is to assess whether adoptive immunotherapy with CAR19 T-cells can be safely used as a bridge to allogenic stem cell transplantation. This is a single centre, single arm dose-escalation phase I study in adults with resistant or relapsed Diffuse Large B cell Lymphoma (DLBCL). Following informed consent, registered patients will undergo an unstimulated leucapheresis for generation of the CD19 specific Chimeric Antigen Receptor T-cells (CAR19 T-cells). Briefly, the CAR19 T-cells will be manufactured by activating autologous peripheral blood mononuclear cells (PBMC) with CD3/28 beads and interleukin-2 for 24 hours followed by transduction with a lentiviral vector encoding the specific CAR19 gene. Cells are then expanded, the CD3/28 beads removed and the final product CAR19 T-cells tested for quality control. The CAR19 T-cells will take ~3 weeks to generate, in which time patients should proceed with a further cycle of standard salvage (recommended IVE (ifosfamide, epirubicin and etoposide)) and should not receive rituximab. Patients will receive pre-conditioning with cyclophosphamide 60mg/kg/day IV for 2 days (day-7 and day-6) followed by fludarabine 25mg/m2/day IV for 5 days (day-5 to day-1) prior to infusion of a single dose of CAR19 T-cells. An escalating dose protocol (2x105 – 5x106 cells/kg) will be employed to identify a minimum effective dose of CAR19 T-cells. Patients will be followed up regularly during the interventional phase (12 months post-CAR19 T- cells infusion) and thereafter annually for a further 2 years. Trial design Trial outline Eligibility Criteria Main Patient Inclusion Criteria Age 16-65 years Confirmed diagnosis of CD19+ DLBCL Primary resistant or relapsed disease failing to achieve metabolic CR to 1st line salvage, or relapse post autograft failing to achieve metabolic CR following a single further cycle of salvage Potential allogeneic transplant candidate Agreement to have a pregnancy test, use adequate contraception for 12 months post-CAR19 T-cell Karnofsky performance status >60 Main Patient Exclusion Criteria Women who are pregnant or lactating Prior allogeneic transplantation Progressive disease following most recent salvage prior to planned leucapheresis Prior history of ischaemic heart disease, dysrhythmias, abnormal ECG, MUGA LVEF<40% Exclusions for proceeding to allogeneic transplantation (active HBV, HCV, HIV; LFT >3 x ULN; CrCl <40 ml/min; or other comorbidities) Known CNS involvement or CVA within 3 months Patients receiving corticosteroids at a dose of > 10mg prednisolone per day (or equivalent) Use of rituximab within the last 2 months Trial end points Primary endpoint: Toxicity evaluation following CAR19 T-cell administration Complete tumour response Feasibility of adequate leucapheresis collection and generation of CAR19 T-cells Secondary endpoints: Engraftment, expansion and persistence of CAR19 T-cells Depletion of B cell compartment Timing and magnitude of cytokine release PET-CT response at 28 days Number of patients proceeding to allogeneic transplantation Contacts Participating site: UCLH Email: ctc.cobalt@ucl.ac.uk Sample size: 12 patients